Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1175045

A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study


Novak, Jurica; Potemkin, Vladimir A.
A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study // Molecular diversity, 26 (2022), 5; 2631-2645 doi:10.1007/s11030-021-10355-8 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1175045 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study

Autori
Novak, Jurica ; Potemkin, Vladimir A.

Izvornik
Molecular diversity (1381-1991) 26 (2022), 5; 2631-2645

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
3CLpro ; COVID-19 ; drug repurposing ; paritaprevir ; QSAR ; radial distribution function

Sažetak
Coronavirus disease 2019 (COVID-19) is caused by novel severe acute respiratory syndrome coronavirus (SARS-CoV-2). Its main protease, 3C-like protease (3CLpro), is an attractive target for drug design, due to its importance in virus replication. The analysis of the radial distribution function of 159 3CLpro structures reveals a high similarity index. A study of the catalytic pocket of 3CLpro with bound inhibitors reveals that the influence of the inhibitors is local, perturbing dominantly only residues in the active pocket. A machine learning based model with high predictive ability against SARS-CoV-2 3CLpro is designed and validated. The model is used to perform a drug-repurposing study, with the main aim to identify existing drugs with the highest 3CLpro inhibition power. Among antiviral agents, lopinavir, idoxuridine, paritaprevir, and favipiravir showed the highest inhibition potential. Enzyme - ligand interactions as a key ingredient for successful drug design.

Izvorni jezik
Engleski

Znanstvena područja
Kemija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)



POVEZANOST RADA


Profili:

Avatar Url Jurica Novak (autor)

Poveznice na cjeloviti tekst rada:

doi pubmed.ncbi.nlm.nih.gov

Citiraj ovu publikaciju:

Novak, Jurica; Potemkin, Vladimir A.
A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study // Molecular diversity, 26 (2022), 5; 2631-2645 doi:10.1007/s11030-021-10355-8 (međunarodna recenzija, članak, znanstveni)
Novak, J. & Potemkin, V. (2022) A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. Molecular diversity, 26 (5), 2631-2645 doi:10.1007/s11030-021-10355-8.
@article{article, author = {Novak, Jurica and Potemkin, Vladimir A.}, year = {2022}, pages = {2631-2645}, DOI = {10.1007/s11030-021-10355-8}, keywords = {3CLpro, COVID-19, drug repurposing, paritaprevir, QSAR, radial distribution function}, journal = {Molecular diversity}, doi = {10.1007/s11030-021-10355-8}, volume = {26}, number = {5}, issn = {1381-1991}, title = {A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study}, keyword = {3CLpro, COVID-19, drug repurposing, paritaprevir, QSAR, radial distribution function} }
@article{article, author = {Novak, Jurica and Potemkin, Vladimir A.}, year = {2022}, pages = {2631-2645}, DOI = {10.1007/s11030-021-10355-8}, keywords = {3CLpro, COVID-19, drug repurposing, paritaprevir, QSAR, radial distribution function}, journal = {Molecular diversity}, doi = {10.1007/s11030-021-10355-8}, volume = {26}, number = {5}, issn = {1381-1991}, title = {A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study}, keyword = {3CLpro, COVID-19, drug repurposing, paritaprevir, QSAR, radial distribution function} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font